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Hyperglycemia and its associated biochemical abnormalities
damage vascular wall cells, especially the endothelium, lead-
ing to an increased risk of cardiovascular events and disease,
as well as microangiopathy and end-organ complications.
In the last decade, accumulating data suggest that vascular
repairmechanisms areimportant tomaintainnormalhome-
ostasis of the arterial wall and to prevent development of
pathologic processes, such as atherosclerosis, restenosis, and
microvascular disease.
Diabetes mellitus, through the impairment of vascular
stem and progenitor cells, entails a defective repair of the
injured endothelium. The biochemical and cellular mech-
anisms that account for reduced or functionally impaired
vascular progenitor cells in diabetes are not fully elucidated,
and this is an intense area of research. Additionally, ther-
apeutic approaches to modulate the endogenous repara-
tive/regenerative processes are of particular interest in the
setting of experimental and clinical diabetes research.
For this special issue of Experimental Diabetes Research,
we invited investigators to contribute with original research
articles and review articles that stimulate the contin-
uing eﬀorts to understand the molecular and cellular
aspects underlying defective vascular repair by means of
stem/progenitor cells in diabetes, as well as the development
of interventions to reverse it.
The journal has received a variety of valuable sub-
missions spanning the pathophysiological and therapeutic
implications of vascular stem/progenitor cells.
Thepathophysiologicalimplicationsarehereindescribed
inthesettingofbothdiabetesandthemetabolicsyndrome.S.
Devaraj and I. Jialal report how number and/or functionality
of endothelial progenitor cells (EPCs) could emerge as a
novel cellular biomarker of endothelial/vascular dysfunction
and cardiovascular disease (CVD) risk in patients with the
metabolicsyndrome.Inthesettingofdiabetes,afocusreview
highlights the central contribution played by bone-marrow-
derived progenitor cells in the development and progression
of chronic complications. Not only are EPCs reduced and
dysfunctional in diabetes, but they also appear to have a
deranged diﬀerentiation capacity, which is shifted toward a
procalciﬁc phenotype that may have a negative impact on
ectopic calciﬁcation and atherosclerosis. Of note, circulating
progenitor cell phenotypes are not limited to EPC, but may
include a variety of lineage-committed cells relevant for the
pathobiology of diabetic complications. As an example, the
level of pericyte progenitor cells (PPCs) in type 2 diabetes
appears to be related to microangiopathy in response to
glucose-lowering therapy. Among disparate complications,
retinopathy has received a special attention: while G. Tremo-
lada and colleagues provide a comprehensive analysis of2 Experimental Diabetes Research
the mechanisms of neoangiogenesis in the diabetic retina,
R. Longeras et al. show how pigment-epithelium-derived-
factor- (PEDF-) 34 attenuates EPC mobilization from the
bone marrow into the bloodstream during retinal neo-
vascularization. This therapeutic approach can now be
considered part of the armamentarium available to reverse
microangiopathy, through regenerative cells. In parallel, S.
Bernardi et al. provided an analysis of cell-based strategies
to counter diabetic complications that have been so far
devised and applied in the experimental and clinical settings.
Besides cell therapies, several other pharmacologic and
nonpharmacologic approaches have shown ability to reverse
EPCs dysfunction in diabetes.
In conclusion, this special issue provides a series of
updated reviews on vascular stem/progenitor cell defects in
diabetes and on the therapeutic approaches to reverse them
and counter diabetic complications. Original contributions
help us to dissect the complexity of vascular stem/progenitor
cell biology and trace the way for future studies in this ﬁeld.
Amazingly, circulating progenitor cells are uncovering an
entirely new scenario in diabetology research: it is all in the
blood!
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